NCT00513565View on ClinicalTrials.gov

A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 13, 2007

Primary Completion Date

May 14, 2009

Study Completion Date

May 14, 2009

Conditions
Depressive Disorder and Anxiety Disorders
Interventions
DRUG

single dose

Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.

Trial Locations (1)

92037

GSK Investigational Site, La Jolla

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00513565 - A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers | Biotech Hunter | Biotech Hunter